Join
Live feed
·
PRReleasevia Quantisnow
Acrivon Therapeutics Inc. logo

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

ByQuantisnow·Wall Street's wire, on your screen.
ACRV· Acrivon Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACRV (Acrivon Therapeutics Inc.) and more on Quantisnow.